Acute Kidney Injury Medical Services in China

Acute Kidney Injury (AKI) is a sudden, often reversible decline in kidney function characterized by an abrupt increase in serum creatinine, decrease in urine output, or both—typically occurring within hours to days. It reflects a spectrum of renal dysfunction ranging from mild tubular injury to severe cortical necrosis and is classified into three stages (Stage 1–3) per the KDIGO (Kidney Disease: Improving Global Outcomes) criteria based on magnitude of creatinine rise and/or urine volume reduction. Pathogenically, AKI arises from three broad mechanisms: prerenal (e.g., hypovolemia, heart failure, sepsis-induced hypoperfusion), intrinsic renal (e.g., acute tubular necrosis from ischemia or nephrotoxins like contrast media, aminoglycosides, NSAIDs, or glomerulonephritis), and postrenal (e.g., urinary tract obstruction from stones, tumors, or prostatic hypertrophy). Cellular injury triggers inflammatory cascades, mitochondrial dysfunction, endothelial activation, and microvascular congestion—culminating in impaired glomerular filtration and tubular transport. Epidemiologically, AKI affects approximately 10–15% of all hospitalized patients globally, with incidence soaring to 30–50% in intensive care units. In China, population-based studies estimate an annual incidence of 2,800–4,200 cases per million adults, disproportionately impacting older adults (>65 years), those with preexisting chronic kidney disease (CKD), diabetes, hypertension, or cardiovascular disease. Key modifiable risk factors include dehydration, uncontrolled sepsis, inappropriate use of nephrotoxic medications, major surgery (especially cardiac and orthopedic), radiocontrast exposure, and delayed recognition of early signs. Non-modifiable risks include advanced age, female sex (in some cohorts), and genetic susceptibility variants (e.g., APOL1 in high-risk populations). Beyond mortality—where Stage 3 AKI carries up to 50% in-hospital death risk—AKI profoundly impairs quality of life: survivors frequently experience persistent fatigue, cognitive slowing, depression, reduced physical endurance, and diminished return-to-work rates. Up to 40% develop new-onset or accelerated CKD within one year, increasing long-term cardiovascular morbidity and dialysis dependence. Early detection via serial creatinine monitoring and urine output tracking remains critical; biomarkers like NGAL and TIMP-2•IGFBP7 show promise for preclinical prediction but are not yet routine in standard practice. Multidisciplinary management—including nephrology consultation within 24 hours of diagnosis—is associated with significantly improved outcomes, underscoring the vital role of dedicated renal medicine services.

Acute Kidney Injury (AKI) is a sudden decline in kidney function, characterized by an abrupt increase in serum creatinine, reduction in urine output, or both, occurring over hours to days. It is classified into three broad pathophysiological categories: prerenal, intrinsic (intrarenal), and postrenal. Prerenal AKI—accounting for approximately 60–70% of cases—results from renal hypoperfusion without structural damage; common causes include hypovolemia (e.g., from gastrointestinal losses, diuretic overuse, or hemorrhage), cardiac output impairment (e.g., acute decompensated heart failure, cardiogenic shock), systemic vasodilation (e.g., sepsis, anaphylaxis), and renal vasoconstriction (e.g., NSAID or calcineurin inhibitor use, hepatorenal syndrome). Intrinsic AKI involves direct parenchymal injury and encompasses glomerular, tubular, interstitial, and vascular disorders. Acute tubular necrosis (ATN), the most frequent intrinsic cause, arises from ischemia (prolonged prerenal states) or nephrotoxins—including aminoglycosides, amphotericin B, radiocontrast media (especially in volume-depleted or diabetic patients), cisplatin, and endogenous toxins like myoglobin (rhabdomyolysis) or hemoglobin (hemolysis). Glomerulonephritis (e.g., ANCA-associated vasculitis, lupus nephritis, anti-GBM disease) and vasculitides may present with rapidly progressive AKI. Acute interstitial nephritis is commonly drug-induced (e.g., PPIs, NSAIDs, beta-lactams, sulfonamides) and associated with fever, rash, eosinophilia, and sterile pyuria. Renal microvascular thrombosis (e.g., thrombotic microangiopathy, malignant hypertension, scleroderma renal crisis) also falls under intrinsic etiologies. Postrenal AKI—comprising ~5–10% of cases—is due to urinary tract obstruction at any level from the renal pelvis to the urethra; common triggers include benign prostatic hyperplasia, ureteral stones, retroperitoneal fibrosis, pelvic malignancies, and iatrogenic causes (e.g., postoperative clots or misplaced ureteral stents). Risk factors for AKI are multifactorial and synergistic. Advanced age (>65 years), preexisting chronic kidney disease (CKD), diabetes mellitus, hypertension, heart failure, liver cirrhosis, and baseline anemia significantly increase susceptibility. Critically ill patients—particularly those requiring mechanical ventilation, vasopressors, or major surgery (especially cardiac or orthopedic)—face markedly elevated risk. Concomitant nephrotoxic exposures (e.g., dual renin-angiotensin-aldosterone system inhibition, contrast-enhanced imaging in high-risk settings) amplify vulnerability. Genetic factors play a modulatory role rather than causing AKI directly; polymorphisms in genes involved in oxidative stress response (e.g., *HMOX1*, *SOD2*), inflammation (*IL10*, *TNF-α*), endothelial function (*eNOS*), and drug metabolism (*CYP3A5*, *ABCC2*) have been associated with differential AKI incidence and recovery trajectories in observational and genome-wide association studies. However, no monogenic disorder is causally linked to typical AKI; instead, genetic variants influence resilience to injury, repair capacity, and progression to CKD post-AKI. Environmental factors contribute substantially: exposure to heavy metals (e.g., lead, mercury, cadmium), organic solvents (e.g., carbon tetrachloride), agricultural toxins (e.g., paraquat), and natural toxins (e.g., aristolochic acid in contaminated herbal remedies) can induce direct tubular toxicity or interstitial inflammation. In low-resource settings, environmental contributors include snake or scorpion envenomation, malaria-associated hemolysis and microvascular obstruction, leptospirosis, and ingestion of contaminated water leading to diarrheal illness with severe volume depletion. Socioeconomic determinants—such as limited access to timely diagnostics, hydration support, or nephrology consultation—further exacerbate environmental risks. Importantly, AKI rarely occurs in isolation; it frequently represents the renal manifestation of systemic dysregulation—whether inflammatory (e.g., cytokine storm in sepsis), metabolic (e.g., hypercalcemia, tumor lysis syndrome), or hemodynamic—and thus requires comprehensive evaluation of the underlying physiological context. Early recognition of precipitating triggers and mitigation of modifiable risk factors remain central to prevention and improved outcomes.

Acute Kidney Injury (AKI) is a sudden, often reversible decline in kidney function characterized by an abrupt reduction in glomerular filtration rate (GFR), leading to accumulation of nitrogenous waste products (e.g., serum creatinine and blood urea nitrogen), dysregulation of fluid and electrolyte homeostasis, and disruption of acid-base balance. AKI is classified into three etiologic categories: prerenal (due to reduced renal perfusion), intrinsic (involving direct parenchymal damage—e.g., acute tubular necrosis, glomerulonephritis, or interstitial nephritis), and postrenal (caused by urinary tract obstruction). Early recognition is critical, as timely intervention significantly improves outcomes and reduces mortality.

Early symptoms of AKI are frequently subtle and nonspecific, particularly in hospitalized or critically ill patients. Many individuals remain asymptomatic until significant functional impairment occurs—often defined as a ≥0.3 mg/dL rise in serum creatinine within 48 hours or a ≥50% increase from baseline over 7 days. Early clinical clues include decreased urine output (oliguria: <400 mL/day in adults; anuria: <100 mL/day), although nonoliguric AKI (urine output >500 mL/day) is common, especially in prerenal or contrast-induced injury. Patients may report fatigue, malaise, mild shortness of breath (due to early volume overload or mild metabolic acidosis), or subjective mental fogginess. In elderly or frail patients, new-onset confusion, lethargy, or subtle changes in cognition may be the only presenting features—reflecting uremic encephalopathy or electrolyte disturbances such as hyperkalemia or hyponatremia. Prerenal AKI may manifest with orthostatic hypotension, tachycardia, dry mucous membranes, or decreased skin turgor; intrinsic AKI may present with low-grade fever, arthralgias, rash, or hematuria in cases of vasculitis or glomerulonephritis.

Typical symptoms emerge as AKI progresses and reflect accumulating toxins and systemic derangements. Oliguria or anuria becomes more pronounced. Uremic symptoms intensify: persistent nausea, vomiting, anorexia, hiccups, and generalized pruritus due to cutaneous calcium-phosphate deposition. Dyspnea may worsen secondary to pulmonary edema from fluid retention or metabolic acidosis-induced tachypnea. Patients may develop hypertension (from sodium and water retention and activation of the renin-angiotensin-aldosterone system) or, paradoxically, hypotension in septic or cardiogenic contexts. Neurological manifestations include tremor, asterixis, myoclonus, somnolence, and, in severe cases, seizures or coma. Pericardial friction rub or pleuritic chest pain may indicate uremic pericarditis or pleuritis—late but ominous signs.

Accompanying symptoms depend on the underlying cause and comorbidities. In sepsis-associated AKI, patients exhibit fever, tachypnea, altered mental status, and signs of organ dysfunction beyond the kidneys. Drug-induced interstitial nephritis commonly presents with fever, rash, eosinophilia, and arthralgia (the classic triad is present in only ~10% of cases). Glomerulonephritis may feature hematuria (microscopic or gross), red blood cell casts, proteinuria (>1 g/day), and hypertension. Postrenal AKI often includes flank or suprapubic pain, palpable bladder distention, or intermittent anuria alternating with diuresis (e.g., in partial obstruction). Hepatorenal syndrome may accompany jaundice, ascites, and coagulopathy. Contrast-induced nephropathy typically follows intravascular iodinated contrast exposure without other obvious precipitants.

Complications of AKI are multifactorial and potentially life-threatening. Electrolyte abnormalities include hyperkalemia (causing peaked T-waves, widened QRS, ventricular arrhythmias), hyperphosphatemia, hypocalcemia (leading to tetany or seizures), and metabolic acidosis (with compensatory Kussmaul respirations). Volume overload results in pulmonary edema, peripheral edema, and heart failure exacerbation. Uremic complications encompass platelet dysfunction (increasing bleeding risk), immune suppression (predisposing to infections), and gastrointestinal mucosal erosion (contributing to upper GI bleeding). Cardiac complications include left ventricular hypertrophy progression, arrhythmias, and uremic pericarditis—potentially progressing to cardiac tamponade. Neurologic sequelae range from reversible encephalopathy to permanent cognitive deficits in survivors of prolonged severe AKI. Critically, AKI markedly increases the risk of progression to chronic kidney disease (CKD) and end-stage renal disease (ESRD), even after apparent recovery.

Diagnosis relies on integrated clinical assessment, serial laboratory testing, and imaging. Serum creatinine remains the cornerstone biomarker, though it lags behind actual GFR changes by 24–48 hours. Blood urea nitrogen (BUN) is less specific but elevated in prerenal states (BUN:Cr ratio >20:1 suggests prerenal etiology). Urinalysis reveals muddy brown granular casts in acute tubular necrosis, dysmorphic RBCs and RBC casts in glomerulonephritis, or eosinophils in interstitial nephritis. Urine electrolytes—including fractional excretion of sodium (FeNa <1% supports prerenal; >2% suggests intrinsic injury) and urea—help differentiate prerenal from intrinsic causes. Renal ultrasound is first-line imaging to exclude obstruction (hydronephrosis) and assess kidney size and echogenicity (small, echogenic kidneys suggest chronic disease; normal or enlarged, echogenic kidneys favor AKI). Doppler ultrasound evaluates renal artery/vein patency and resistive index. In select cases, renal biopsy is indicated when diagnosis remains uncertain—especially with suspected glomerulonephritis, vasculitis, or atypical interstitial nephritis—and provides definitive histopathologic classification.

Differential diagnosis must distinguish AKI from chronic kidney disease (CKD) with acute decompensation, which requires evaluating prior creatinine trends, kidney size on imaging, and presence of CKD markers (e.g., anemia, bone mineral abnormalities). Prerenal azotemia must be differentiated from intrinsic AKI using FeNa, urine sediment, and clinical context. Postrenal obstruction must be ruled out in all AKI cases before attributing injury to intrinsic causes. Other mimics include rapidly progressive glomerulonephritis (RPGN), thrombotic microangiopathies (e.g., HUS/TTP), malignant hypertension, and hepatorenal syndrome. Functional AKI—such as that induced by NSAIDs or ACE inhibitors in volume-depleted patients—must be distinguished from structural injury. Importantly, AKI can coexist with other organ failures (e.g., acute respiratory distress syndrome, hepatic failure), necessitating a systems-based diagnostic approach rather than isolated renal evaluation.

Acute Kidney Injury (AKI) is a sudden decline in glomerular filtration rate (GFR) occurring over hours to days, characterized by accumulation of nitrogenous waste products (e.g., serum creatinine, blood urea nitrogen), electrolyte imbalances, and fluid overload. Prompt recognition and intervention are critical to prevent progression to chronic kidney disease or death. Management is stratified according to etiology—prerenal (e.g., hypovolemia, cardiac failure), intrinsic (e.g., acute tubular necrosis, glomerulonephritis, vasculitis, interstitial nephritis), or postrenal (e.g., urinary tract obstruction)—and severity, typically staged using the KDIGO criteria (based on serum creatinine rise and/or urine output). Treatment is multidisciplinary, with nephrology-led care central to optimal outcomes.

Conservative treatment forms the cornerstone of AKI management and must be initiated immediately upon diagnosis. Prerenal AKI mandates rapid volume resuscitation with isotonic crystalloids (e.g., 0.9% saline or balanced solutions such as lactated Ringer’s), guided by hemodynamic assessment (central venous pressure, dynamic parameters like stroke volume variation if available) and avoidance of fluid overload. In cardiorenal syndrome, diuretics (e.g., intravenous furosemide) may be used cautiously with close monitoring of renal perfusion and electrolytes. For intrinsic AKI, supportive measures include strict avoidance of nephrotoxins (e.g., NSAIDs, aminoglycosides, iodinated contrast), correction of hyperkalemia (calcium gluconate for cardiac membrane stabilization, insulin–glucose infusion, sodium polystyrene sulfonate or patiromer, or newer potassium binders like sodium zirconium cyclosilicate), management of metabolic acidosis (sodium bicarbonate only if pH <7.15 and hemodynamically stable), and meticulous fluid balance monitoring. Nutritional support is essential: protein intake should be moderated (0.8–1.0 g/kg/day) to reduce nitrogen load without inducing catabolism; caloric intake must be sufficient (25–30 kcal/kg/day) to preserve lean body mass. Early mobilization and prevention of complications—including deep vein thrombosis (prophylactic enoxaparin unless contraindicated), stress ulcer prophylaxis, and delirium screening—are integral components.

Pharmacologic therapy is etiology-specific. In immune-mediated AKI (e.g., ANCA-associated vasculitis, lupus nephritis, or drug-induced interstitial nephritis), prompt immunosuppression is life- and kidney-saving: high-dose intravenous methylprednisolone (500–1000 mg/day for 3 days), followed by oral prednisone taper, combined with cyclophosphamide or rituximab per consensus guidelines. Antibiotics are indicated for pyelonephritis or sepsis-related AKI, with empiric broad-spectrum coverage adjusted per culture results. Diuretic resistance may necessitate combination therapy (e.g., furosemide plus metolazone), though evidence for improved renal recovery remains limited. Renin-angiotensin-aldosterone system inhibitors (RAASi) should be temporarily withheld during AKI episodes due to risk of hyperkalemia and worsening GFR but may be cautiously reintroduced once recovery is established and electrolytes stabilized. Novel agents remain investigational; while natriuretic peptides (e.g., carperitide) showed promise in early trials, they are not standard-of-care outside select research settings.

Surgical intervention is reserved for specific indications. Relief of urinary obstruction—whether from benign prostatic hyperplasia, ureteral stones, or malignancy—is urgent and often achieved via minimally invasive techniques: ureteral stent placement or percutaneous nephrostomy under ultrasound or fluoroscopic guidance. In cases of retroperitoneal fibrosis or pelvic malignancy causing bilateral obstruction, surgical decompression or tumor debulking may be required. Rarely, surgical nephrectomy is considered for irreversible, infected, or massively hemorrhagic kidneys (e.g., in severe vasculitis with cortical necrosis), though this is exceptional. Vascular surgery may be indicated for renal artery or vein thrombosis when anticoagulation alone is insufficient. Importantly, dialysis access creation (e.g., tunneled catheter or arteriovenous fistula) is procedural rather than therapeutic per se but is indispensable for patients requiring renal replacement therapy (RRT).

China offers distinct advantages in AKI management, particularly through its integrated, high-volume nephrology infrastructure. Over 95% of tertiary hospitals have dedicated nephrology departments equipped with advanced continuous renal replacement therapy (CRRT) platforms, enabling precise hemodynamic control in critically ill patients. Chinese nephrologists demonstrate exceptional expertise in CRRT anticoagulation strategies—including regional citrate anticoagulation (RCA), which reduces bleeding risk and extends filter life—and routinely apply real-time biomarker-guided protocols (e.g., TIMP-2•IGFBP7 testing) for early AKI risk stratification. The national AKI surveillance network (launched 2018) facilitates standardized data collection across >1,200 centers, driving evidence-based protocol refinement. Moreover, China’s robust traditional medicine integration permits adjunctive use of evidence-informed herbal formulations—such as Huangqi (Astragalus membranaceus) extracts in clinical trials showing reduced inflammation and improved tubular repair—under strict pharmacovigilance oversight. Tele-nephrology platforms now extend specialist consultation to rural regions, significantly reducing time-to-intervention.

Recovery advice emphasizes longitudinal follow-up and risk mitigation. Patients discharged after AKI require nephrology follow-up within 2 weeks, with serial serum creatinine, eGFR, and urinalysis at 1, 3, 6, and 12 months to detect incomplete recovery or progression. Blood pressure must be tightly controlled (<130/80 mmHg), preferably with RAASi if tolerated, given their renoprotective effects in residual dysfunction. Lifestyle modifications include sodium restriction (<2 g/day), avoidance of NSAIDs and herbal nephrotoxins (e.g., aristolochic acid-containing herbs), smoking cessation, and annual influenza/pneumococcal vaccination. Patients should be counseled on signs of recurrence (e.g., oliguria, edema, fatigue) and instructed to seek immediate evaluation for acute illness, dehydration, or new medications. Long-term cardiovascular risk assessment is mandatory, as AKI independently increases incident heart failure and mortality. Finally, shared decision-making regarding advance care planning—including goals of care discussions about future RRT—should occur early in recovery for high-risk patients. With timely, comprehensive, and individualized management, up to 70–80% of hospitalized AKI patients achieve full renal recovery; however, even partial recovery confers increased long-term morbidity, underscoring the necessity of sustained, coordinated care.